Skip to main content
Log in

SGLT2 inhibitors cost effective versus sulfonylureas in T2DM

PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2017 US dollars

  2. glucagon-like peptide-1

Reference

  • Bagepally BS, et al. Cost Utility of Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Metformin Monotherapy Failed Type 2 Diabetes Patients: A Systematic Review and Meta-analysis. Value in Health : 18 Nov 2019. Available from: URL: https://doi.org/10.1016/j.jval.2019.09.2750

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

SGLT2 inhibitors cost effective versus sulfonylureas in T2DM. PharmacoEcon Outcomes News 842, 29 (2019). https://doi.org/10.1007/s40274-019-6421-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-019-6421-5

Navigation